Excellent
Fully Aligned
Patient Risk:
Low
Summary
The AI assessment claim is fully supported by the provided FDA label text (Warnings and Precautions 5.1 and Renal Impairment 8.6) and is not contradicted.
Category Scores
Accurate Statements
Severe hypocalcemia risk is increased in patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m2), including dialysis-dependent patients, and can be life-threatening/fatal.
Supported by 5.1 (increased risk in advanced CKD including dialysis-dependent patients; severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases reported) and reiterated in 8.6 (greater risk; severe hypocalcemia with hospitalization, life-threatening events and fatal cases reported postmarketing).
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The response accurately characterizes a labeled risk in an at-risk population and does not introduce incorrect or missing safety guidance beyond what was claimed.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement